Breaks Categories: Stock Spotlights

ThursdayDec 09, 2021 2:30 pm

CBDNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Study Marks First Phase 2 Trial to Evaluate Cannabinol as Therapeutic Option for Disease Treatment

InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following the acquisition of BayMedica Inc. in October that created an industry leader in the manufacture and commercialization of rare cannabinoids, management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products. In late September, InMed commenced the 755-201-EB study, its phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). A recent article…

Continue Reading

TuesdayDec 07, 2021 2:52 pm

CBDNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Focusing on Continued Growth of Top-Line Revenue, Bottom-Line Results

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has officially entered the second phase of a three-phase development strategy that captures its expansion plan in Florida after installing, commissioning and loading five of 30 planned modular grow pods, which are already growing plants. RWB, through its subsidiary Red White & Bloom Florida LLC (“RWBFL”), is fast-tracking the remaining 25 pods. Collectively, the 30 pods will provide about 19,000 square feet of operating space with an expected yield of 10,000 pounds of high-quality flower annually. RWB anticipates this annual yield will generate $30 million in additional revenue. RWBFL also successfully…

Continue Reading

MondayDec 06, 2021 1:32 pm

CBDNewsBreaks – Why Marijuana Company of America Inc. (MCOA) Is ‘One to Watch’

Marijuana Company of America (OTC: MCOA), which operates and invests in the cannabis sector directly, continues to grow its business. MCOA focuses on remaining fiscally conscious while further establishing itself in the legalized THC, hemp and CBD industries by offering unique exposure to the global cannabidiol sector. “The company intends to continue to leverage its premium brand hemp-based products with investments in and collaboration with existing and new strategic partners,” reads a recent article. “MCOA strives to develop a comprehensive selection of synergistic companies that provides consistent value to its shareholders. Furthermore, its vertically integrated business model provides companies and…

Continue Reading

ThursdayDec 02, 2021 12:42 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) has embarked on its most ambitious study yet, the HYPER-H21-4. The study is among several geared towards evaluating DehydraTECH(TM)-processed CBD for the potential treatment of hypertension and heart disease. The learnings from two studies, HYPER-H21-1 and HYPER-H21-2, whose results are already out, have led to the HYPER-H21-4 clinical study. Further, blood pressure findings from HYPER-H21-3 will be reportable by the end of January 2022 and will contribute to the HYPER-H21-4. The study protocols for HYPER-H21-4 are being readied for submission to the Independent Review Board (“IRB”), and approval is expected by January 2022. HYPER-H21-4, which…

Continue Reading

TuesdayNov 30, 2021 11:49 am

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Strategy Toward Potential Therapeutics for Diseases with High Unmet Needs

InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio) that may inhibit or slow the progression of neurogenerative diseases – such as Alzheimer’s, Parkinson’s, Huntington’s and others – by providing protection in a population of affected neurons. Furthermore, the application demonstrates the cannabinoid can also be used to promote neurite outgrowth, signifying the potential to enhance neuronal function. According to InMed’s Senior VP Pre-Clinical Research & Development Dr. Eric Hsu, who is quoted in a recent article, “This PCT patent application advances our strategy directed towards researching and…

Continue Reading

WednesdayNov 24, 2021 2:29 pm

CBDNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Makes Expansion of Platinum Vape Brand Top Priority

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently announced the completion of an agreement for the transition of the management at Platinum Vape LLC (“PV”), having settled all additional PV acquisition price considerations. “RWB estimates that production of PV vape carts will increase to over 450,000 in November, a projection that has made expansion of the PV brand a top priority. Michigan and California are proving to be the two vital promising markets pushing for this growth, prompting focus on PV and streamlining its operations,” reads a recent article. The management transition saw the addition of Shea Alderete…

Continue Reading

WednesdayNov 24, 2021 1:22 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently conducted a study on canines in collaboration with an independent testing laboratory. The analysis evaluated nicotine benzoate and polacrilex plasma levels in 40 anesthetized male beagle dogs comparing Lexaria’s recently developed, advanced DehydraTECH 2.0 nicotine formulation to concentration-matched controls. The dogs’ blood samples were taken every few minutes over the course of two hours. “The results from the study showed that the generic nicotine benzoate pouch required about 45 minutes to reach its peak delivery rate. In comparison, the DehydraTECH-nicotine benzoate pouch reached peak delivery rates at both eight minutes and again at 30…

Continue Reading

TuesdayNov 16, 2021 3:04 pm

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities

InMed Pharmaceuticals (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system to manufacture pharmaceutical-grade cannabinoids that are otherwise too rare to be acquired in abundance. Through BayMedica, its recent acquisition, InMed also has capabilities in both yeast biosynthesis and chemical synthesis, catering to the large and growing health and wellness consumer markets. “The cannabis plant is made up of over 100 unique cannabinoids, many of which are only found in trace amounts,” reads a recent article. “With so many of these…

Continue Reading

FridayNov 12, 2021 11:34 am

CBDNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Eyeing Q1 2022 Delivery of Highest-Quality Retail Products from Florida Grow Operations

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently completed phase one of an aggressive three-phase development strategy for its Florida facilities, located in Apopka and Sanderson. Phase one entailed the rapid development of the Apopka facility. RWB also announced that it had commenced operation in late September after receiving regulatory approval to begin cultivation. “The initial licensed area in Apopka is capable of producing 85g of flower per plant, translating to projected annual revenue in excess of $10 million. The Apopka facility will supply RWB’s phase two of the strategy, which entails activating thirty 16’ by 40’ customized,…

Continue Reading

ThursdayNov 11, 2021 1:32 pm

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters into Cannabinoid Science

Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research initiatives in medical cannabis in order to become a leader in the discovery, development, manufacturing and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases. The company also signed an agreement to begin scientific clinical trials on the use of…

Continue Reading